SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff, which traders link to the Democrats midterm gains and fears that political pushback could slow AI and data-center expansion, has put SPY in focus as tech and semiconductor shares unwind. The community is divided between calling the decline an overreaction and buying the dip versus expecting further downside amid volatility and selling pressure.

Netlist, Inc. engages in the design, manufacture and sale of memory subsystems for the computing and communications markets. Its products include enterprise SSD, embedded flash, memory module, lightning DDR5 DIMM, SK hynix, AI server. The company was founded by Jayesh Bhakta, Chun Ki Hong and Christopher Lopes in June 2000 and is headquartered in Irvine, CA.

Netlist Inc

NLST is under pressure amid a broad selloff in technology and memory stocks, with traders debating whether concerns about AI/data-center investment and policy risks or company-specific factors are driving the decline. Many are treating the pullback as a buying opportunity ahead of the Q3 report, while watching for an SK Hynix agreement and developments in Netlists Kingston litigation.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

Rigels quarterly results and early VEPPANU launch are driving discussion: traders are encouraged by the drugs initial uptake and record product sales, but some focus on the earnings miss, weaker margins, and cash burn. The stocks sharp decline has sharpened the debate over whether VEPPANUs growth potential outweighs the disappointing headline results.

Listed Funds Trust - Roundhill Magnificent Seven ETF

Roundhill Magnificent Seven ETF

MAGS is under pressure as traders question whether Big Techs heavy AI and data-center spending will generate returns quickly enough to offset its effect on free cash flow. The community is split between fears of a deeper tech correction and views that the selloff is a rotation or pullback creating a buying opportunity.

X-Energy, Inc. engages in the development of advanced small modular nuclear reactors and fuel technology for clean energy generation. Its solutions include Xe-100 and TRISO-X. The company was founded by Kam Ghaffarian and Eben Mulder in 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-Energy Inc

XE is drawing attention amid a sharp selloff, with traders citing broader weakness in nuclear stocks and concerns about post-IPO share supply and bearish analyst coverage. Some are buying the dip on the strength of Amazon-backed reactor projects and federal support, while others worry that commercialization and meaningful revenue remain years away.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings disappointing Q3 results and lowered full-year outlook triggered a sharp selloff, with traders criticizing rising costs and managements heavy investment in its Predictions business. The main debate is whether that investment can build a growth engine or instead leaves DraftKings vulnerable to competition from Kalshi and Polymarket and delays profitability.

Sezzle, Inc. engages in the operation of a digital payment platform that enables bank-to-bank transfer of money between consumers and businesses. The company was founded by Charlie G. Youakim, Killian Brackey and Paul V. Paradis on January 4, 2016 and is headquartered in Minneapolis, MN.

Sezzle Inc.

Sezzles Q3 results beat expectations and management raised its FY2026 outlook while issuing a positive initial FY2027 forecast, fueling a sharp rally. Bulls point to continued growth and profitability, while some traders warn that valuation and a slower projected growth pace could weigh on the stock; short-squeeze talk is speculative.

Teradyne, Inc.. The Group's principal activity is to design, manufacture, sell and service automatic test equipment for electronic companies. It operates in two segments: Semiconductor Test Systems and System Test Group. Semiconductor Test Systems segment designs, manufactures, sells and supports Semiconductor Test products and services on a world wide basis. Systems Test Group segment is comprised of 3 business units: Mil/Aero, Commercial Board Test and Diagnostic Solutions. It also operates in the Semiconductor Test; Military/Aerospace test, Commercial Circuit Board test and Automotive Diagnostics test. On 14-Nov-2008, it acquired Eagle Test Systems Inc, On 24-Jan-2008, it acquired Nextest Systems Corporation ('Nextest').

Teradyne, Inc.

Teradynes sharp selloff despite a strong quarterly beat is driving discussion, with traders pointing to cautious near-term guidance, margin pressure and valuation concerns. Some see the drop as a buying opportunity, while others question whether AI-related chip-testing demand can sustain the stocks prior gains.

Bitmine Immersion Technologies, Inc. is a technology company focused on acquiring, holding, and actively managing ETH as its primary treasury reserve asset. It prioritizes digital ecosystem services, such as consultancy and advisory works. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

BMNR is under pressure amid a broad crypto and tech selloff, with traders linking its decline to weakness in Bitcoin and Ethereum. Many complain that the stock is falling harder than ETH and criticize Tom Lees stewardship, while others see the discount to asset value and share buybacks as reasons to buy the dip.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

NVIDIA is caught in a sharp semiconductor selloff as traders worry that post-midterm calls for tighter data-center rules could slow AI infrastructure spending and chip demand. The community is split between seeing the drop as an overreaction and buying opportunity, and expecting more downside if AI-capex growth or data-center expansion slows.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business UpdatePR NewswireBURLINGAME, Calif., Nov. 5, 2026 Reached alignment with the FDA on the final design of the...

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year

Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this Year Enliven Therapeutics Appoints Kristine Ball to Board of Directors Ahead of Planned Phase 3 Trial Initiation this YearPR NewswireBURLINGAME, Calif., Oct. 14, 2026Accomplished...

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia

Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid Leukemia Enliven Therapeutics Announces FDA Alignment on ENABLE-2 Phase 3 Trial Design for Relcobatinib (ELVN-001) in Previously Treated Chronic Myeloid...

This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday

Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.read more...

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics to Present at Upcoming Investor Conferences Enliven Therapeutics to Present at Upcoming Investor Conferences PR Newswire BURLINGAME, Calif., Sept. 3, 2026 BURLINGAME, Calif., Sept. 3, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a...

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting PR Newswire BURLINGAME, Calif., Aug. 31, 2026...

Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

William Blair initiates Enliven Therapeutics (ELVN) with Outperform, highlighting ELVN-001's strong CML trial data & $8.8B market potential.read more...

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update PR Newswire BURLINGAME, Calif., Aug. 5, 2026 Announced positive Phase 1 clinical data for ELVN-001 in CML...

What to Know About This $345,000 Enliven Insider Sale as the Stock Soars 130%

Key PointsA director of Enliven Therapeutics reported selling 10,000 shares in open-market transactions on June 5, 2026, for a total value of $345,000...

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally

What to Know About OrbiMed's $39 Million Enliven Therapeutics Stock Sale Amid a 130% Rally...

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Enliven Therapeutics Inc

ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Enliven Therapeutics also announced it has aligned with the U.S. Food and Drug Administration (FDA) on key elements of its planned late-stage trial.</li><li>Separately, Enliven priced an upsized public offering to raise capital for its programs.</li><li>According to data from Koyfin, all 10 analysts covering ELVN stock rate it ‘Buy.’</li></ul>Shares of Enliven Therapeutics (ELVN) jumped 12% on Friday, on track to close its fourth consecutive day in the green, after the company announced that its experimental drug ELVN-001 showed encouraging results in patients with chronic myeloid leukemia (CML), a type of blood cancer, in an updated Phase 1 study.The stock has risen about 33% this week and is on track to post its best week since last March if gains hold.<h2 class="st-heading-2">ELVN Trial Outcome</h2>As of March 2026, the drug produced meaningful responses in heavily pretreated patients, many of whom had already tried multiple existing therapies, the company said on Thursday. In one key group receiving an 80 mg daily dose, 48% of patients achieved a major molecular response — a standard measure of treatment success in CML — while 30% reached a deeper response. The drug was generally well tolerated, with most side effects being mild. However, 6% of patients discontinued the study due to adverse events, the company noted.The company also announced it has aligned with the U.S. Food and Drug Administration (FDA) on key elements of its planned late-stage trial. Enliven expects to begin the late-stage trial in the second half of 2026.Separately, Enliven priced an upsized public offering to raise capital for its programs. “The gross proceeds from the offering are expected to be around $400.0 million before deducting underwriting discounts and commissions and other offering expenses,” the company said in its pricing announcement. ELVN-001 is now the main focus of Enliven’s pipeline after the company decided last year to explore strategic alternatives for its other clinical program, ELVN-002.<h2 class="st-heading-2">How Did ELVN Retail Traders React?</h2>On Stocktwits, retail sentiment around ELVN stock fell from ‘extremely bullish’ to ‘bullish’ levels over the past 24 hours, while message volume was ‘extremely high.’A Stocktwits user said that they believe the share price has upside left because the positive clinical data support a higher overall valuation. &nbsp;<stembedurl>https://www.stocktwits.com/BobBobbertonnn/message/656278417</stembedurl>According to data from Koyfin, all 10 analysts covering ELVN stock rate it ‘Buy.’ The stock has a 12-month average price target of $60.11, representing a potential upside of about 49% from the stock’s last closing price.<a href="https://stocktwits.com/symbol/ELVN">ELVN stock</a> has gained 195% this year.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mnts-posts-biggest-single-day-fall-this-year-what-s-driving-today-s-sell-off/cZKd5xXR75J">MNTS Posts Biggest Single-Day Fall This Year – What’s Driving Today’s Sell-Off?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Enliven Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried multiple existing therapies, Enliven Therapeutics said.

iShares Russell 2000 ETF

Vanguard Total Stock Market ETF

Fundamental investor

Technical trader

A mix of both

Fundamental analysis looks at earnings, valuation, and business quality, while technical analysis focuses on chart patterns, price action, and indicators, and many investors blend the two. How do you decide what to buy: fundamentals or technicals? Vote and explain your reasoning in the comments.

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '26	-$0.49	--	--	N/A
Q3 '26	-$0.45	-$0.36	19.62%	BEAT
Q2 '26	-$0.39	-$0.49	-26.56%	MISSED
Q1 '26	-$0.44	-$0.38	14.33%	BEAT
Q4 '25	-$0.38	-$0.48	-24.68%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

ELVN Earnings

Latest Earnings Results: Q3 '26

Historical Earnings